Tedizolid Population Pharmacokinetics, Exposure Response, and Target Attainment

January 30, 2016 at 8:46 am

Antimicrobial Agents and Chemotherapy November 2014 V.58 N.11 P.6462-6470

Flanagan, J. Passarell, Q. Lu, J. Fiedler-Kelly, E. Ludwig, and P. Prokocimer

aCubist, San Diego, California, USA

bCognigen Corporation, Buffalo, New York, USA

Tedizolid phosphate is a novel antibacterial prodrug that is rapidly and extensively converted to its active moiety, tedizolid. We developed a population pharmacokinetics (PK) model for tedizolid using pooled data from seven densely and sparsely sampled clinical trials evaluating oral and intravenous tedizolid.

Model-derived exposure estimates were evaluated for relationships to select efficacy and safety outcomes. A two-compartment model with sigmoidal absorption, absolute bioavailability, and linear elimination described the PK data well.

Variability was small (clearance, 31% coefficient of variation; volume, 13.4% coefficient of variation), and absolute bioavailability was high (86%). No clinically significant covariate effects on tedizolid PK were found.

Based on phase 3 data evaluating 200-mg once-daily tedizolid for acute bacterial skin and skin structure infections (ABSSSI), no relationships were seen between various efficacy outcomes and estimated tedizolid exposure; the estimated exposure range (free-drug area under the concentration-time curve over 24 h at steady state [AUCss(0–24)], 7 to 50 μg · h/ml) in these patients was modest.

Safety data modeling, using once-daily doses of up to 400 mg, showed a small increase in the probability of an adverse event with increasing model-estimated tedizolid exposure; no such relationship was observed when specifically evaluating the 200-mg dose.

There were no trends in neutrophil or platelet counts with increasing tedizolid exposure.

Target attainment simulations for 200-mg tedizolid indicated a 98.31% probability of attaining the target measure (AUC for the free, unbound fraction of a drug [fAUC]/MIC = 3) against a Staphylococcus aureus strain for which the MIC was ≤0.5 μg/ml.

These findings support 200-mg tedizolid once daily as the optimum dose for treatment of ABSSSI.

abstract

http://aac.asm.org/content/58/11/6462.abstract

PDF

http://aac.asm.org/content/58/11/6462.full.pdf

Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Infecciones en piel y tej blandos, Sepsis, Update. Tags: .

Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis


Calendar

January 2016
M T W T F S S
« Dec   Feb »
 123
45678910
11121314151617
18192021222324
25262728293031

Most Recent Posts


%d bloggers like this: